ICAT strengthens RegMed XB Pilot Factory with new location at Plus Ultra Utrecht
− 1 min readThe Innovation Center for Advanced Therapies (ICAT), part of UMC Utrecht, has moved into Plus Ultra Utrecht at Utrecht Science Park. This step strengthens the regional infrastructure for regenerative medicine and supports the activities of the RegMed XB Pilot Factory.
ICAT focuses on accelerating the development and clinical translation of Advanced Therapy Medicinal Products (ATMPs), including cell, tissue, and gene therapies. By combining early-stage development with GMP-compliant manufacturing, ICAT helps bridge the gap between academic discovery and clinical application.
Within the RegMed XB Pilot Factory, ICAT collaborates with other pilot lines, including the Smart BioMaterials Consortium (SBMC), NecstGen, ReGEN Biomedical, and Leiden University Medical Center. Together, these pilot lines strengthen the infrastructure and ecosystem needed to bring breakthrough regenerative therapies to patients.
Karel Loerts, Managing Director of ICAT, explains:
Our move to Plus Ultra Utrecht provides an inspiring work environment and strengthens our connection with research and production facilities at Utrecht Science Park. Together with our partners within RegMed XB, we look forward to developing new therapies, methods, and medical technologies that will advance future healthcare.
Through the Shared Open Innovation Lab at Plus Ultra Utrecht, researchers, clinicians, start-ups, and industry partners can collaborate closely, accelerating innovation and knowledge sharing both regionally and nationally.
This move reinforces ICAT’s role in building the infrastructure required to bring regenerative medicine from research to patient care and highlights RegMed XB’s central role as a driving force behind the advanced therapies ecosystem in the Netherlands.